Evaxion Reports Strong Immune Responses in EVX-01 Phase 2 Data

Evaxion A/S (NASDAQ: EVAX) presented phase 2 trial data for its personalized cancer vaccine EVX-01, showing strong immune responses in advanced melanoma patients. The data, shared at the SITC 2026 Annual Meeting, includes 89% vaccine target precision and sustained T-cell responses. Evaxion's AI-Immunology platform demonstrated strong predictive performance, with significant association between predictions and actual T-cell responses.

Evaxion A/S (NASDAQ:EVAX) presented phase 2 trial data for its cancer vaccine EVX-01 at the Society for Immunotherapy of Cancer Annual Meeting. The data showed significant T-cell responses and a strong association between its AI-Immunology platform's predictions and actual immune responses. The trial reported an Objective Response Rate of 75% in advanced melanoma patients.

Evaxion A/S reported phase 2 data for EVX-01, showing neoantigen-specific T-cell responses and significant AI prediction correlation (p<0.001) in advanced melanoma. This follows earlier clinical and immune-response data. Further clinical or regulatory progress would be a larger catalyst.

Evaxion A/S (NASDAQ: EVAX) reported new biomarker data from its phase 2 trial of EVX-01, a personalized cancer vaccine for advanced melanoma. The data showed 89% of vaccine targets triggered an immune response, validating the company's AI-Immunology™ platform. The findings were presented at the SITC 2026 Annual Meeting.

Evaxion A/S (NASDAQ: EVAX) will present new data on EVX-04, an off-the-shelf therapeutic vaccine for acute myeloid leukemia (AML), at the ASH 2026 Meeting. The data validate EVX-04's potential, showing broad patient coverage and immune response induction in preclinical models. EVX-04 targets non-conventional endogenous retrovirus (ERV) tumor antigens, selected using Evaxion's AI-Immunology platform.

Evaxion (NASDAQ: EVAX) will present new biomarker data from its phase 2 trial with personalized cancer vaccine EVX-01 at the SITC 2026 Annual Meeting. The trial, involving advanced melanoma patients, showed a 75% objective response rate. EVX-01 is designed with Evaxion's AI-Immunology platform and is being evaluated as a treatment for advanced melanoma.